Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a micro-cap biotech company currently valued at $8.77 million and trading at $6.96, will present clinical data from its Phase 1/2 trial of solnerstotug, alone and in combination with Regeneron’s PD-1 inhibitor Libtayo (cemiplimab), at the upcoming European Society for Medical Oncology Congress in Berlin.
The presentation, scheduled for October 17, 2025, will feature results from the dose expansion cohort studying patients with advanced solid tumors that have shown resistance to prior PD-(L)1 therapy.
Dr. Kyriakos Papadopoulos, Co-Director of Clinical Research at START in San Antonio, will deliver the presentation titled "Results from a Phase 1 expansion cohort of solnerstotug (pH-selective anti-VISTA antibody) combined with cemiplimab in patients with advanced solid tumors resistant to prior PD-(L)1 therapy."
Solnerstotug is Sensei’s lead product candidate, designed as a conditionally active antibody that blocks the VISTA checkpoint selectively within the low pH tumor microenvironment. According to the company, VISTA acts as a suppressor of T cells by binding the receptor PSGL-1.
The clinical-stage biotechnology company focuses on developing what it calls Tumor Microenvironment Activated biologics (TMAb), which are conditionally active therapeutics designed to function specifically within the tumor microenvironment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.